Following an almost two-week long trial, a federal jury in Delaware ruled Merck’s patent for hepatitis C treatments was valid. Merck acquired the drug patent when it purchased Idenix Pharmaceuticals in 2014.
In 2015, Gilead Science’s hit almost $20 billion in revenue from Harvoni and Sovaldi. The jury’s award represents a 10 percent royalty rate from sales of the drugs through this August, according to the report.
Michele Rest, a spokeswoman for Foster City, Calif.-based Gilead Sciences, said the drugmaker disagrees with the verdict and plans to file an appeal, according to the report.
More articles on supply chain:
American Red Cross needs donors amid seasonal blood shortage
Amazon conducts first drone delivery to a customer
Pharma manufacturer Lonza to acquire Capsugel for $5.5B: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
